Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE)

B Solomon, A Mersiades, C Brown, S Dawson, S Wong, L Tan, S Yip, Y Cheung, H Jurkovic, M Walker, S Kao, CK Lee, G Newnham, K O'Byrne, S Parakh, K Jasas, V Bray, M Stockler, T John, N Pavlakis